Anti-Deamidated Gliadin Peptide (DGP) IgG

Key Features and Values

– Wide variety of sample types to simplify inclusion into routine serology work-up
– No observed matrix effect in paediatric samples excludes pre-treatment steps
– Ready to use reagents reduces hands-on time for assay preparation
– Long shelf life cost-effective solution by reducing wastage due to expired kits
– Suitable for inclusion on automated plate systems simplifies scale-up of test volume

Product Description

Anti Deamidated Gliadin Peptide (DGP) IgG is an indirect solid phase enzyme immunometric assay (ELISA) kit designed for the quantitative measurement of IgG class antibodies directed against Deamidated Gliadin Peptides (DGP) in human serum or plasma.  Anti Deamidated Gliadin Peptide (DGP) IgG kit is intended for laboratory use only.

Scientific Description
Coeliac disease, also known as gluten sensitive enteropathy is primarily a disease of the infant organism.  It is caused by a hypersensitivity reaction in response to gliadin, a protein being present in many cereals.  This, non IgE mediated food allergy leads to massive malabsorption disturbances and is characterised by a complete atrophy of the villi and hyperplasia of the crypts of the upper intestine.  Accordingly patients suffering from coeliac disease must maintain a gluten free diet for the rest of their life.
Gliadins are proteins containing high amounts of the amino acids prolin and glutamine.  These proteins belong to the nutritive tissue of the grain seeds of wheat, oat, barley and rye and are responsible for the baking properties of the flour.  Due to the possibilities of the highly specific and sensitive serological determination of IgA and IgG antibodies against DGP the invasive procedures of biopsies can be given up.  In the past several biopsies have been done with patients when coeliac disease was suspected, after a period of a gluten-free diet and also after a specific gluten challenge; DGP antibodies titer has been proven to correlate very well with the morphological appearance of the mucosa of the upper intestine.
It has been well documented that DGP antibodies level fall very quickly after a gluten free diet has begun and rise immediately after restoring gluten to the diet.  Thus the serological test represents a reliable method to monitor patients, and in particular children and teenagers, for their adherence to the gluten-free diet.
Publications

1. Chartrand LJ, Seidman EG. Celiac disease is a lifelong disorder. Clin.Invest.Med., Vol. 19, 357-361, 1996
2. Cornell HJ. Coeliac disease: A review of the causative agents and their possible mechanisms of action. Amino Acids, Vol. 10, 1-19, 1996
3. Cronin CC, Feighery A, Ferriss JB, Liddy C, Shanahan F, Feighery C. High prevalence of celiac disease among patients with insulin-dependent (type I) diabetes mellitus. Am.J Gastroenterol., Vol. 92, 2210-2212, 1997
4. Jokinen J, Peters U, Maki M, Miettinen A, Collin P. Celiac sprue in patients with chronic oral mucosal symptoms. J Clin.Gastroenterol., Vol. 26, 23-26, 1998
5. Taminiau JA. Celiac disease. Curr.Opin.Pediatr., Vol. 8, 483-486, 1996
6. Williams CN. Celiac disease: past, present and future. Can.J Gastroenterol., Vol. 11, 647-649, 1997

Download
Please enter your email address to download the DKO106-Anti-DGP-IgG-IFU.pdf
Code: DKO106
Clinical Area: ,
Incubation: 30+30+15 min
Sensitivity: 100%
Specificity: >94.1%
Classification: IVD, CE
Number of Tests: 96
Sample Type: Serum/Plasma
Sample Volume: 10 µL (1:100 predilution)
Assay Range: N/A